Pet Therapy Effects on Pain, Emotional and Physiological Responses in Children Undergoing Allergy Testing
Launched by MEHTAP METİN KARAASLAN · Mar 12, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
In recent years, there has been a marked increase in the prevalence of allergic diseases. In particular, the incidence of allergic respiratory diseases has almost doubled in the last two decades. This increase is thought to be related to increased sensitization to both indoor and outdoor allergens. Indoors, house dust mites remain the most important cause of allergic sensitization in infants. With increasing age, the prevalence of aeroallergens, especially pollen, increases and sensitization to indoor and outdoor allergens reaches similar levels around three years of age. Sensitization to b...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • No previous allergy testing
- • 3-6 years old
- • Stable hemodynamics
- • No chronic disease
- • The child has no intellectual or neurological disability
- • The mother has no obstacle to communication
- • Mother is literate
- • Families and children agree to participate in the study.
- Exclusion Criteria:
- • The child does not meet the inclusion criteria
- • The mother does not meet the inclusion criteria
- • Child's and mother's unwillingness to participate in the study
About Mehtap Meti̇n Karaaslan
Mehtap Metin Karaaslan is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes, Ms. Karaaslan leads initiatives that prioritize rigorous study design, ethical standards, and regulatory compliance. Her expertise spans various therapeutic areas, and she fosters collaboration among multidisciplinary teams to ensure the successful execution of clinical trials. Through her leadership, she aims to contribute significantly to the development of novel therapies and improve the overall landscape of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported